Inhibition of vascular adhesion protein-1 modifies hepatic steatosis in vitro and in vivo

Non-alcoholic fatty liver illness (NAFLD) is related to weight problems, insulin resistance and dyslipidaemia and at present is estimated to have an effect on as much as a 3rd of all people in developed nations. Current commonplace of look after sufferers varies in accordance with illness stage, however consists of way of life interventions frequent insulin sensitizers, antioxidants and lipid modifiers. However, so far particular therapies have proven little histological or fibrosis stage enchancment in giant scientific trials, and there may be nonetheless no licensed remedy for NAFLD. Given the excessive prevalence, restricted remedy choices and important screening prices for the general inhabitants, new therapies are urgently required.
 To assess the potential for inhibition of the amine oxidase enzyme vascular adhesion protein-1 (VAP-1) to change hepatic lipid accumulation in NAFLD. We have used immunochemical and qPCR evaluation to doc expression of VAP-1 and key practical proteins and transporters throughout the NAFLD spectrum. We then utilised hepatocytes in tradition and human precision reduce liver slices in live performance with selective enzyme exercise inhibitors to check the consequences of activating the semicarbazide-sensitive amine oxidase exercise of VAP-1 on hepatic lipid uptake and triglyceride export.
We confirmed that growing severity of NAFLD and development to cirrhosis was related to a big enhance in hepatocellular VAP-1 expression. Hepatocytes in vitro uncovered to recombinant VAP-1 and its substrate methylamine confirmed elevated lipid accumulation as decided by quantification of Oil Red O uptake. This was recapitulated utilizing hydrogen peroxide, and lipid accumulation was accompanied by adjustments in expression of the lipid transporter molecules FABP3, FATP6, insulin receptor subunits and PPARα.
Human liver tissue uncovered to recombinant VAP-1 or substrates for endo/exogenous VAP-1 produced much less triglyceride than untreated tissue and demonstrated a rise in steatosis. This response may very well be inhibited through the use of bromoethylamine to inhibit the SSAO exercise of VAP-1, and mice poor in VAP-1/AOC3 additionally demonstrated diminished steatosis on excessive fats weight loss plan. Exposure of human liver tissue to methylamine to activate VAP-1 resulted in elevated expression of FABP2 and 4, FATP3-5, caveolin-1, VLDLR, PPARGC1 and genes related to the inflammatory response.
 Our information verify that the elevations in hepatic VAP-1 expression reported in nonalcoholic steatohepatitis can contribute to steatosis, metabolic disturbance and irritation. This means that concentrating on the semicarbazide delicate amine oxidase capability of VAP-1 could symbolize a helpful adjunct to different therapeutic methods in NAFLD. A murine mannequin of NAFLD was additionally used to find out the results of VAP-1 knockout and gene expression arrays had been used to quantify the consequences of VAP-1 exercise on key lipid modifying and proinflammatory gene expression.

Autophagy alleviates hypoxia-induced blood-brain barrier damage through regulation of CLDN5 (claudin 5)

 

Blood-brain barrier (BBB) disruption is a key occasion in triggering secondary harm to the central nervous system (CNS) underneath stroke, and is often related to irregular macroautophagy/autophagy in mind microvascular endothelial cells (BMECs). However, the underlying mechanism of autophagy in sustaining BBB integrity stays unclear. Here we report that in BMECs of sufferers struggling stroke, CLDN5 (claudin 5) abnormally aggregates in the cytosol accompanied by autophagy activation. In vivo zebrafish and in vitro cell research reveal that BBB breakdown is partially attributable to CAV1 (caveolin 1)-mediated redistribution of membranous CLDN5 into the cytosol underneath hypoxia.

Meanwhile, autophagy is activated and contributes primarily to the degradation of CAV1 and aggregated CLDN5 in the cytosol of BMECs, due to this fact assuaging BBB breakdown. Blockage of autophagy by genetic strategies or chemical compounds aggravates cytosolic aggregation of CLDN5, ensuing in severer BBB impairment. These information display that autophagy capabilities in the safety of BBB integrity by regulating CLDN5 redistribution and present a possible therapeutic technique for BBB disorder-related cerebrovascular illness.

BBB: blood-brain barrier; BECN1: beclin 1; BMEC: mind microvascular endothelial cell; CAV1: caveolin 1; CCA: frequent carotid artery; CLDN5: claudin 5; CNS: central nervous system; CQ: chloroquine; HIF1A: hypoxia inducible issue 1 subunit alpha; MCAO: center cerebral artery occlusion-reperfusion; OCLN: occludin; ROS: reactive oxygen species; STED: stimulated emission depletion; TEER: trans-endothelial electrical resistance; TEM: transmission electron microscopy; TJ: tight junction; TJP1: tight junction protein 1; UPS: ubiquitin-proteasome system.

Inhibition of vascular adhesion protein-1 modifies hepatic steatosis in vitro and in vivo

Transcriptomic evaluation of tobacco-flavored E-cigarette and menthol-flavored E-cigarette publicity in the human center ear

Electronic cigarettes (e-cigarettes) are essentially the most broadly used digital nicotine supply techniques and are designed to mimic smoking and help in smoking cessation. Although the quantity of e-cigarette customers is growing quickly, particularly amongst younger adults and adolescents, the potential well being impacts and biologic results of e-cigarettes nonetheless have to be elucidated. Our earlier research demonstrated the cytotoxic results of digital liquids (e-liquids) in a human center ear epithelial cell (HMEEC-1) line, which had been affected by the producer and flavoring brokers regardless of the presence of nicotine.

In this research, we aimed to judge the gene expression profile and determine potential molecular modulator genes and pathways in HMEEC-1 uncovered to 2 completely different e-liquids (tobacco- and menthol-flavored). HMEEC-1 was uncovered to e-liquids, and RNA sequencing, practical evaluation, and pathway evaluation had been performed to determine the resultant transcriptomic adjustments. A complete of 843 genes had been differentially expressed following publicity to the tobacco-flavored e-liquid, amongst which 262 genes had been upregulated and 581 had been downregulated.

Upon publicity to the menthol-flavored e-liquid, a complete of 589 genes had been differentially expressed, amongst which 228 genes had been upregulated and 361 had been downregulated. Among the signaling pathways related to the differentially expressed genes mediated by tobacco-flavored e-liquid publicity, a number of key molecular genes had been recognized, together with IL6 (interleukin 6), PTGS2 (prostaglandin-endoperoxide synthase 2), CXCL8 (C-X-C motif chemokine ligand 8), JUN (Jun proto-oncogene), FOS (Fos proto-oncogene), and TP53 (tumor protein 53).

Goat Anti Caveolin 1 Polyclonal Antibody

CPBT-65031GC 0.1 mg
EUR 861

Polyclonal Goat Anti-Caveolin 1 Antibody

AMM04925G 0.1 mg
EUR 484
Description: A polyclonal antibody raised in Goat that recognizes and binds to Human Goat Anti-Caveolin 1 . This antibody is tested and proven to work in the following applications:

Anti-human Caveolin-1 antibody

A1506-50
EUR 468

Anti-Caveolin-1 antibody

STJ92050 200 µl
EUR 197
Description: Rabbit polyclonal to Caveolin-1.

Anti-Caveolin-1 antibody

STJ92051 200 µl
EUR 197
Description: Caveolin-1 is a protein encoded by the CAV1 gene which is approximately 20,4 kDa. Caveolin-1 is localised to the Golgi apparatus membrane and cell membrane. It is involved in eNOS activation and regulation, focal adhesion and lipoprotein metabolism. It is a scaffolding protein that makes up the main component of the caveolae plasma membranes found in most cell types. The protein links integrin subunits to the tyrosine kinase FYN which is an initiating step in coupling integrins to the Ras-ERK pathway and promoting cell cycle progression. Caveolin-1 is expressed in the brain. Mutations in the CAV1 gene may result in pulmonary hypertension and lipodystrophy. STJ92051 was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. This polyclonal antibody detects endogenous levels of Caveolin-1 protein.

Anti-Caveolin 1 antibody

STJ70728 100 µg
EUR 359

anti- Caveolin-1 antibody

FNab01313 100µg
EUR 505.25
Description: Antibody raised against Caveolin-1

anti- Caveolin-1 antibody

FNab01314 100µg
EUR 505.25
Description: Antibody raised against Caveolin-1

Anti-Caveolin-1 antibody

PAab01313 100 ug
EUR 355

Polyclonal Goat anti-GST α-form

GST-ANTI-1 50 uL
EUR 280

Caveolin-1 Polyclonal Antibody

ES1872-100ul 100ul
EUR 279
Description: A Rabbit Polyclonal antibody against Caveolin-1 from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, WB, ELISA

Caveolin-1 Polyclonal Antibody

ES1872-50ul 50ul
EUR 207
Description: A Rabbit Polyclonal antibody against Caveolin-1 from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, WB, ELISA

Caveolin-1 Polyclonal Antibody

ES1873-100ul 100ul
EUR 279
Description: A Rabbit Polyclonal antibody against Caveolin-1 from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, IHC, IF, WB, ELISA

Caveolin-1 Polyclonal Antibody

ES1873-50ul 50ul
EUR 207
Description: A Rabbit Polyclonal antibody against Caveolin-1 from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, IHC, IF, WB, ELISA

Caveolin-1 Polyclonal Antibody

ABP50873-003ml 0.03ml
EUR 158
Description: A polyclonal antibody for detection of Caveolin-1 from Human, Mouse, Rat. This Caveolin-1 antibody is for WB, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human Caveolin-1 around the non-phosphorylation site of Y14

Caveolin-1 Polyclonal Antibody

ABP50873-01ml 0.1ml
EUR 289
Description: A polyclonal antibody for detection of Caveolin-1 from Human, Mouse, Rat. This Caveolin-1 antibody is for WB, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human Caveolin-1 around the non-phosphorylation site of Y14

Caveolin-1 Polyclonal Antibody

ABP50873-02ml 0.2ml
EUR 414
Description: A polyclonal antibody for detection of Caveolin-1 from Human, Mouse, Rat. This Caveolin-1 antibody is for WB, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human Caveolin-1 around the non-phosphorylation site of Y14

Caveolin-1 Polyclonal Antibody

ABP50874-003ml 0.03ml
EUR 158
Description: A polyclonal antibody for detection of Caveolin-1 from Human, Mouse, Rat. This Caveolin-1 antibody is for WB, IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human Caveolin-1 at AA range: 100-180

Caveolin-1 Polyclonal Antibody

ABP50874-01ml 0.1ml
EUR 289
Description: A polyclonal antibody for detection of Caveolin-1 from Human, Mouse, Rat. This Caveolin-1 antibody is for WB, IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human Caveolin-1 at AA range: 100-180

Caveolin-1 Polyclonal Antibody

ABP50874-02ml 0.2ml
EUR 414
Description: A polyclonal antibody for detection of Caveolin-1 from Human, Mouse, Rat. This Caveolin-1 antibody is for WB, IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human Caveolin-1 at AA range: 100-180

Caveolin-1 Polyclonal Antibody

40684-100ul 100ul
EUR 252

Caveolin-1 Polyclonal Antibody

40684-50ul 50ul
EUR 187

Polyclonal Caveolin-1 Antibody

APG02445G 0.05ml
EUR 528
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human Caveolin-1 . This antibody is tested and proven to work in the following applications:

Polyclonal Caveolin-1 Antibody

APG02446G 0.1ml
EUR 484
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human Caveolin-1 . This antibody is tested and proven to work in the following applications:

Anti-Caveolin-1 Rabbit Monoclonal Antibody (RM325)

A1840-50
EUR 311

Anti-Caveolin-3 Rabbit Monoclonal Antibody

M00990 100ug/vial
EUR 397
Description: Rabbit Monoclonal Caveolin-3 Antibody. Validated in WB and tested in Human, Mouse, Rat.

Anti-Caveolin-2 Rabbit Monoclonal Antibody

M01574 100ug/vial
EUR 397
Description: Rabbit Monoclonal Caveolin-2 Antibody. Validated in IP, IF, IHC, WB and tested in Human.

Rabbit Polyclonal Antibody to Human TDP1

TG2016 250 units
EUR 414

Anti-Caveolin-1/CAV1 Antibody

PA1514 100ug/vial
EUR 334

Anti-Caveolin-1/CAV1 Antibody

PB9165 100ug/vial
EUR 334

Anti-Caveolin 1, Biotinylated antibody

STJ73171 100 µg
EUR 359

Anti-Caveolin-1 Rabbit Monoclonal Antibody, Clone#RM325

M00179-2 100uL
EUR 385
Description: Anti-Caveolin-1 Rabbit Monoclonal Antibody, Clone#RM325 tested in WB, IHC, reactive to Human

anti-Caveolin 1

YF-PA10691 100 ug
EUR 403
Description: Rabbit polyclonal to Caveolin 1

Myeloid/lymphoid or mixed-lineage leukemia translocated to 1 (MLLT1) polyclonal antibody

ABP-PAB-10851 100 ug Ask for price

Caveolin-1 Antibody

33331-100ul 100ul
EUR 252

Caveolin-1 Antibody

33331-50ul 50ul
EUR 187

Caveolin-1 Antibody

48674-100ul 100ul
EUR 333

Caveolin-1 Antibody

48674-50ul 50ul
EUR 239

Caveolin 1 Antibody

AF5372 200ul
EUR 304
Description: Caveolin 1 Antibody detects endogenous levels of total Caveolin 1.

Caveolin-1 Antibody

AF6386 200ul
EUR 304
Description: Caveolin-1 Antibody detects endogenous levels of total Caveolin-1.

Caveolin-1 Antibody

AF0126 200ul
EUR 304
Description: Caveolin-1 antibody detects endogenous levels of total Caveolin-1.

Caveolin- 1 Antibody

ABF0126 100 ug
EUR 438

Caveolin 1 Antibody

ABF5372 100 ug
EUR 438

Caveolin- 1 Antibody

ABF6386 100 ug
EUR 438

Caveolin-1 Antibody

A1010-50
EUR 403

Caveolin 1 antibody

20R-1949 50 ug
EUR 281
Description: Rabbit polyclonal Caveolin 1 antibody

Caveolin 1 antibody

20R-2291 50 ug
EUR 281
Description: Rabbit polyclonal Caveolin 1 antibody

Caveolin 1 antibody

70R-31113 100 ug
EUR 327
Description: Rabbit polyclonal Caveolin 1 antibody

Caveolin 1 antibody

70R-49479 100 ul
EUR 244
Description: Purified Polyclonal Caveolin 1 antibody

Caveolin 1 antibody

70R-49480 100 ul
EUR 244
Description: Purified Polyclonal Caveolin 1 antibody

Caveolin 1 antibody

70R-35767 100 ug
EUR 327
Description: Rabbit polyclonal Caveolin 1 antibody

Caveolin-1 Antibody

8219-002mg 0.02 mg
EUR 171.82
Description: Caveolin-1 Antibody: Caveolin-1 is a scaffolding protein that is the main component of the caveolae plasma membranes found in most cell types (1). The protein links integrin subunits to the tyrosine kinase FYN, an initiating step in coupling integrins to the Ras-ERK pathway and promoting cell cycle progression (2). The gene is a tumor suppressor gene candidate and a negative regulator of the Ras-p42/44 mitogen-activated kinase cascade (3). Mutations in this gene have been associated with Berardinelli-Seip congenital lipodystrophy (4).

Caveolin-1 Antibody

8219-01mg 0.1 mg
EUR 436.42
Description: Caveolin-1 Antibody: Caveolin-1 is a scaffolding protein that is the main component of the caveolae plasma membranes found in most cell types (1). The protein links integrin subunits to the tyrosine kinase FYN, an initiating step in coupling integrins to the Ras-ERK pathway and promoting cell cycle progression (2). The gene is a tumor suppressor gene candidate and a negative regulator of the Ras-p42/44 mitogen-activated kinase cascade (3). Mutations in this gene have been associated with Berardinelli-Seip congenital lipodystrophy (4).

Rabbit Polyclonal Antibody to Human Topoisomerase IIb

TG2010-3 250 units
EUR 414

Rabbit Polyclonal Antibody to Human Topoisomerase IIIb

TG2010-4 250 units
EUR 380

Anti-Caveolin-3 Antibody

A00990 100ug
EUR 765
Description: Rabbit Polyclonal Caveolin-3 Antibody. Validated in IF, WB and tested in Human, Mouse, Rat.

Anti-Phospho-Caveolin-1 (Y14) antibody

STJ90210 200 µl
EUR 197
Description: Rabbit polyclonal to Phospho-Caveolin-1 (Y14).

Caveolin 1 (CAV1) Polyclonal Antibody (Human, Mouse)

4-PAA214Hu01
  • EUR 232.00
  • EUR 2285.00
  • EUR 574.00
  • EUR 289.00
  • EUR 208.00
  • 100ul
  • 10ml
  • 1ml
  • 200ul
  • 20ul
Description: A Rabbit polyclonal antibody against Human, Mouse Caveolin 1 (CAV1)

Caveolin-1 (phospho Tyr14) Polyclonal Antibody

ES1279-50ul 50ul
EUR 207
Description: A Rabbit Polyclonal antibody against Caveolin-1 (phospho Tyr14) from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, WB, ELISA

Caveolin-1 (phospho Tyr14) Polyclonal Antibody

ES1279-100ul 100ul
EUR 279
Description: A Rabbit Polyclonal antibody against Caveolin-1 (phospho Tyr14) from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, WB, ELISA

Caveolin-1 (phospho Tyr14) Polyclonal Antibody

ABP50280-003ml 0.03ml
EUR 158
Description: A polyclonal antibody for detection of Caveolin-1 phospho Tyr14) from Human, Mouse, Rat. This Caveolin-1 phospho Tyr14) antibody is for WB, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human Caveolin-1 around the phosphorylation site of Y14

Caveolin-1 (phospho Tyr14) Polyclonal Antibody

ABP50280-01ml 0.1ml
EUR 289
Description: A polyclonal antibody for detection of Caveolin-1 phospho Tyr14) from Human, Mouse, Rat. This Caveolin-1 phospho Tyr14) antibody is for WB, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human Caveolin-1 around the phosphorylation site of Y14

Caveolin-1 (phospho Tyr14) Polyclonal Antibody

ABP50280-02ml 0.2ml
EUR 414
Description: A polyclonal antibody for detection of Caveolin-1 phospho Tyr14) from Human, Mouse, Rat. This Caveolin-1 phospho Tyr14) antibody is for WB, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human Caveolin-1 around the phosphorylation site of Y14

Polyclonal CAV1 / Caveolin 1 Antibody (Internal)

APG02439G 0.05mg
EUR 484
Description: A polyclonal antibody raised in Goat that recognizes and binds to Human CAV1 / Caveolin 1 (Internal). This antibody is tested and proven to work in the following applications:

Caveolin 1 (CAV1) Polyclonal Antibody (Mouse)

4-PAA214Mu01
  • EUR 236.00
  • EUR 2338.00
  • EUR 586.00
  • EUR 294.00
  • EUR 209.00
  • 100ul
  • 10ml
  • 1ml
  • 200ul
  • 20ul
Description: A Rabbit polyclonal antibody against Mouse Caveolin 1 (CAV1)

Anti-Sumo 1 Rabbit Monoclonal Antibody

M00631-1 100ug/vial
EUR 397
Description: Rabbit Monoclonal Sumo 1 Antibody. Validated in IP, IF, IHC, WB and tested in Human, Mouse, Rat.

Anti-Cytokeratin 1 Rabbit Monoclonal Antibody

M01639-1 100ug/vial
EUR 397
Description: Rabbit Monoclonal Cytokeratin 1 Antibody. Validated in WB and tested in Human, Mouse, Rat.

Rabbit Polyclonal Antibody to Human Topoisomerase I (Rabbit Serum)

TG2012-2 250 ul
EUR 380

Caveolin-1 Rabbit mAb

A19006-100ul 100 ul
EUR 410

Caveolin-1 Rabbit mAb

A19006-200ul 200 ul
EUR 571

Caveolin-1 Rabbit mAb

A19006-20ul 20 ul
EUR 221

Caveolin-1 Rabbit mAb

A19006-50ul 50 ul
EUR 287

Anti-CETP Antibody (polyclonal rabbit anti-human, mouse, rat) with goat anti-rabbit HRP secondary antibody

EXOAB-CETP-1 25 ul
EUR 219

Mouse Monoclonal Antibody to Human Topoisomerase IIα

TG2010-1 50 units
EUR 369

Caveolin 1 (CAV1) Polyclonal Antibody (Human, Mouse), APC

4-PAA214Hu01-APC
  • EUR 323.00
  • EUR 2969.00
  • EUR 836.00
  • EUR 409.00
  • EUR 210.00
  • 100ul
  • 10ml
  • 1ml
  • 200ul
  • 20ul
Description: A Rabbit polyclonal antibody against Human, Mouse Caveolin 1 (CAV1). This antibody is labeled with APC.

Caveolin 1 (CAV1) Polyclonal Antibody (Human, Mouse), Biotinylated

4-PAA214Hu01-Biotin
  • EUR 295.00
  • EUR 2235.00
  • EUR 671.00
  • EUR 358.00
  • EUR 212.00
  • 100ul
  • 10ml
  • 1ml
  • 200ul
  • 20ul
Description: A Rabbit polyclonal antibody against Human, Mouse Caveolin 1 (CAV1). This antibody is labeled with Biotin.

Caveolin 1 (CAV1) Polyclonal Antibody (Human, Mouse), Cy3

4-PAA214Hu01-Cy3
  • EUR 390.00
  • EUR 3917.00
  • EUR 1073.00
  • EUR 504.00
  • EUR 239.00
  • 100ul
  • 10ml
  • 1ml
  • 200ul
  • 20ul
Description: A Rabbit polyclonal antibody against Human, Mouse Caveolin 1 (CAV1). This antibody is labeled with Cy3.

Caveolin 1 (CAV1) Polyclonal Antibody (Human, Mouse), FITC

4-PAA214Hu01-FITC
  • EUR 279.00
  • EUR 2395.00
  • EUR 688.00
  • EUR 347.00
  • EUR 188.00
  • 100ul
  • 10ml
  • 1ml
  • 200ul
  • 20ul
Description: A Rabbit polyclonal antibody against Human, Mouse Caveolin 1 (CAV1). This antibody is labeled with FITC.

Caveolin 1 (CAV1) Polyclonal Antibody (Human, Mouse), HRP

4-PAA214Hu01-HRP
  • EUR 297.00
  • EUR 2589.00
  • EUR 741.00
  • EUR 371.00
  • EUR 199.00
  • 100ul
  • 10ml
  • 1ml
  • 200ul
  • 20ul
Description: A Rabbit polyclonal antibody against Human, Mouse Caveolin 1 (CAV1). This antibody is labeled with HRP.

Caveolin 1 (CAV1) Polyclonal Antibody (Human, Mouse), PE

4-PAA214Hu01-PE
  • EUR 279.00
  • EUR 2395.00
  • EUR 688.00
  • EUR 347.00
  • EUR 188.00
  • 100ul
  • 10ml
  • 1ml
  • 200ul
  • 20ul
Description: A Rabbit polyclonal antibody against Human, Mouse Caveolin 1 (CAV1). This antibody is labeled with PE.

Rabbit Anti-Human ATF2 Polyclonal Antibody, aa.serine 60-64 or 42-46

CPB-944RH 100 ul
EUR 460

Rabbit Anti-Human ATF2 Polyclonal Antibody, aa.67-71 or 49-53

CPB-945RH 100 ul
EUR 460

Rabbit Anti-Human ATF2 Polyclonal Antibody, aa.69-73 or 51-55

CPB-946RH 100 ul
EUR 460

Rabbit Anti-Human ATF2 Polyclonal Antibody, aa.71-75 or 53-57

CPB-947RH 100 ul
EUR 460

Rabbit Anti-Human ATF2 Polyclonal Antibody, aa.110-114 or 92-96

CPB-948RH 100 ul
EUR 460

Caveolin 1 (CAV1) Antibody

abx122002-100ug 100 ug
EUR 391

Caveolin 1 (CAV1) Antibody

20-abx125305
  • EUR 495.00
  • EUR 704.00
  • EUR 356.00
  • 100 ul
  • 200 ul
  • 50 ul

Caveolin 1 (CAV1) Antibody

20-abx116788
  • EUR 732.00
  • EUR 398.00
  • 150 ul
  • 50 ul

Caveolin-1 (CAV1) Antibody

20-abx137365
  • EUR 704.00
  • EUR 328.00
  • EUR 230.00
  • 100 ug
  • 20 ug
  • 5 ug

Caveolin 1 (CAV1) Antibody

20-abx100474
  • EUR 398.00
  • EUR 133.00
  • EUR 1107.00
  • EUR 537.00
  • EUR 314.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Caveolin 1 (CAV1) Antibody

20-abx100475
  • EUR 411.00
  • EUR 133.00
  • EUR 1135.00
  • EUR 551.00
  • EUR 314.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Caveolin 1 (CAV1) Antibody

20-abx100476
  • EUR 425.00
  • EUR 133.00
  • EUR 1177.00
  • EUR 578.00
  • EUR 328.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Caveolin 1 (pT14) Antibody

20-abx009682
  • EUR 314.00
  • EUR 467.00
  • EUR 203.00
  • 100 ul
  • 200 ul
  • 30 ul

Caveolin 1 (pY14) Antibody

abx010493-100ug 100 ug
EUR 439

Under menthol-flavored e-liquid remedy, MMP9 (matrix metallopeptidase 9), PTGS2 (prostaglandin-endoperoxide synthase 2), MYC (MYC proto-oncogene, bHLH transcription issue), HMOX1 (heme oxygenase 1), NOS3 (nitric oxide synthase 3), and CAV1 (caveolin 1) had been predicted as key genes. In addition, we recognized associated mobile processes, together with inflammatory responses, oxidative stress and carcinogenesis, underneath publicity to tobacco- and menthol-flavored e-liquids. We recognized differentially expressed genes and associated mobile processes and gene signaling pathways after e-cigarette publicity in human center ear cells. These findings could present helpful proof for understanding the impact of e-cigarette publicity.